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Background: Mitochondrial aldehyde dehydrogenase 2 (ALDH2) detoxifies reactive aldehydes in the micro- and
macrovasculature. These substrates, including methylglyoxal and 4-hydroxynonenal formed from glucose and lipids,
cause protein carbonylation and mitochondrial dysfunction, forming advanced glycation end products (AGEs). The
present study aimed to confirm the association between the inactive ALDH2*2 allele and diabetic retinopathy (DR).
Methods: A retrospective longitudinal analysis was conducted, among 234 Japanese patients with type 2 diabetes
mellitus (DM) (156 males and 78 females) who had no DR signs at baseline and were treated for more than half a
year. The ALDH2*1/*2 alleles were determined using a real-time TaqMan allelic discrimination assay.
Multivariate-adjusted hazard ratios (HRs) and 95% confidential intervals (CIs) for the cumulative incidence of the
development of DR were examined using a Cox proportional hazard model, taking drinking habits and the serum
γ-glutamyltransferase (GGT) level into consideration.
Results: The frequency of the ALDH2*2 allele was 22.3%. Fifty-two subjects cumulatively developed DR during the
follow-up period of 5.5 ± 2.5 years. The ALDH2*2 allele carriers had a significantly higher incidence of DR than the
non-carriers (HR: 1.92; P = 0.02). The incidence of DR was significantly higher in the drinkers with the ALDH2*2 allele
than in those with the ALDH2*1/*1 genotype (HR: 2.61; P = 0.03), while the incidence of DR in the non-drinkers did
not differ significantly between the ALDH2 genotype groups (P > 0.05). The incidence of DR was significantly higher
in the ALDH2*2 allele carriers with a high GGT level than in the non-carriers with a high or low GGT level
(HR: 2.45; P = 0.03; and HR: 2.63; P = 0.03, respectively).
Conclusions: To the best of our knowledge, this is the first report of a significant association between the ALDH2*2
allele and the incidence of DR. These findings provide additional evidence that ALDH2 protects both
microvasculature and macrovasculature against reactive aldehydes generated under conditions of sustained
oxidative stress, although further investigations in larger cohorts are needed to verify the results.
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Hyperglycemia promotes vascular damage in patients with
diabetes mellitus (DM) via multiple mechanisms [1].
The presence of diabetic retinopathy (DR) is associated
with an over two-fold higher risk of coronary events
which increases with the progression of DR [2]. Advanced
glycation end product (AGE) formation and oxidative stress
in the mitochondria of the vasculature have been proposed
to contribute to both micro- and macrovascular complica-
tions [1-3]. The mitochondrial aldehyde dehydrogenase 2
(ALDH2) expressed in the micro- and macrovasculature
detoxifies the reactive aldehydes formed from glucose and
lipids [4]. These substrates, including methylglyoxal, glyoxal,
and 4-hydroxynonenal (4-HNE) cause protein carbonyla-
tion and mitochondrial dysfunction, forming AGEs [3-5].
A recent meta-analysis of genome-wide association
studies identified a variant, rs671, in the ALDH2 gene
that was associated with variations in blood pressure (BP)
in East Asians [6]. According to that analysis, the wild-type
ALDH2*1 allele was identified as a risk factor for an
elevated BP. Conversely, the allele was associated with
a reduced risk of coronary artery disease (CAD). These
associations are believed to be largely mediated by alcohol
consumption, because this variant determines an individ-
ual’s tolerance to alcohol by altering the ALDH2 enzym-
atic activity [7]. Accordingly, the authors interpreted the
deleterious effects of the ALDH2*1 allele on BP to be
balanced by the protective effects of alcohol consumption
on the lipid profile, thus resulting in a net reduction in
the risk of CAD. We, however, have shown that alcohol
consumption, even less than one drink/day, increases
the risk of hypertension in Japanese individuals with the
inactive ALDH2*2 allele [8].
Based on this information, the present study aimed to
confirm that ALDH2 potentially protects the microvascu-
lature and macrovasculature against reactive aldehydes
and carbonyl stress, regardless of the etiology [1,3-9]. We
therefore investigated the association between the inactive
ALDH2*2 allele and the risk of DR among Japanese subjects
with type 2 DM.
Methods
A retrospective longitudinal analysis was conducted, among
234 Japanese patients with type 2 DM (156 males and 78
females) who had no DR signs at baseline and had been
treated at the Jinnouchi Clinic, Diabetes Care Center
in Kumamoto, Japan, for more than half a year between
February 2002 and January 2011. The study protocol
was approved by the institutional ethics committee,
and written informed consent was obtained from each
subject. The study was performed in accordance with the
Declaration of Helsinki.
DR was diagnosed by a professional ophthalmologist using
direct ophthalmoscopy or fundus fluorescein angiography.DR was staged as no retinopathy, nonproliferative diabetic
retinopathy (NPDR) or proliferative diabetic retinopathy
(PDR) according to the criteria determined at the third
national ophthalmology conference held in 1985. The
occurrence of DR was defined as having no DR signs in
both eyes at baseline and developing NPDR or PDR in
either of the eyes during the follow-up period.
Height and weight were measured using standard pro-
tocols, and the body mass index (BMI) was calculated.
Fasting blood samples were analyzed using the standard
methods of the Japan Society of Clinical Chemistry. The
blood pressure (BP) was measured after the subject rested
in a sitting position. Information regarding smoking
and alcohol drinking habits was obtained via face-to-
face interviews conducted by medical staff members.
Based on their alcohol drinking habits, the subjects
were categorized as non-drinkers (abstainers) or drinkers
(including social drinkers). Additionally, the level of serum
γ-glutamyltransferase (GGT) was measured and used as a
biomarker for alcohol intake [10,11].
Genomic DNA was prepared from whole blood using
a DNA purification kit (Flexi Gene DNA kit, QIAGEN,
Hilden, Germany). The ALDH2*1/*2 alleles were deter-
mined using a real-time TaqMan allelic discrimination assay
(Applied Biosystems, CA, USA) according to the protocols
provided by the manufacturer (assay no. C_11703892_10).
All reagents were purchased from Applied Biosystems. To
ensure the genotyping quality, we included DNA samples
as internal controls, hidden samples of known genotypes
and negative controls (water).
The data are presented as the means ± standard deviations
or proportions for categorical variables. Student’s t-test and
Fisher’s exact test were used for comparisons of the con-
tinuous and categorical variables, respectively. Multivariate-
adjusted hazard ratios (HRs) and 95% confidential intervals
(CIs) for the cumulative incidence of DR were examined
using a Cox proportional hazard model. In the multivariate
model, we included the following variables as covariates:
gender, BMI, diabetes duration, hemoglobin A1c (HbA1c),
systolic BP and the GGT level. The interactive effect and
combined effect between the ALDH2 genotypes and the
GGT levels at the baseline on the development of DR were
also analyzed using a Cox proportional hazard model.
Kaplan-Meier survival curves were used to estimate the
DR-free survival according to the ALDH2 genotypes or
the combinations of the genotypes and the GGT levels.
The GGT levels at the baseline were dichotomized
according to the median values for males and females.
Factors influencing the GGT level were determined
using a univariate linear regression analysis with calcu-
lations of the β coefficient. The longitudinal relation-
ship between the incidence of DR and the GGT values
during the observation period was also assessed using an
autoregressive model based on the generalized estimating
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to be statistically significant. All statistical analyses were
performed using the SPSS software package (version 17.0,
SPSS Inc., Chicago, IL).
Results
The frequency of the ALDH2*2 allele was 22.3%, and
that of the ALDH2*1/*1, *1/*2 and *2/*2 genotypes was
61.1%, 33.3% and 5.6%, respectively. The observed
genotype frequency distribution was consistent with
the Hardy-Weinberg equilibrium. Since the number of
subjects with the ALDH2*2/*2 genotype was too small
to assess the effects of the genotype on the development
of DR, the ALDH2*1/*2 and ALDH2*2/*2 genotypes were
combined in the subsequent analysis. The demographic
characteristics of the subjects with the ALDH2*1/*1 geno-
type (non-carriers) and the ALDH2*2 allele carriers at base-
line are shown in Additional file 1: Table S1. The frequency
of drinkers and the mean GGT values were significantly
lower in the ALDH2*2 allele carriers than in the non-
carriers. The mean GGT value was significantly higher
in the drinkers than in the non-drinkers (58.5 ± 70.0 IU/L
vs. 34.6 ± 31.6 IU/L, P < 0.01). The median GGT value was
37 IU/L for the males and 26 IU/L for the females.
The mean follow-up duration was 5.5 ± 2.5 years. Fifty-
two subjects cumulatively developed DR (51 cases of NPDR
and one cases of PDR) during the follow-up period, and
the incidence of DR was 58.6/1,000 person-years. The
ALDH2*2 allele carriers exhibited a higher incidence of
DR than the non-carriers (70.2/1,000 person-years and
50.7/1,000 person-years, respectively). A significantly higher
incidence of DR among the ALDH2*2 allele carriers than
the non-carriers was also observed in the Cox proportional
hazard model (HR: 1.92; P = 0.02) (Additional file 1: Table
S2, Figure 1a). In this model, the incidence of DR increased
(HR: 1.26; P < 0.01) with increasing HbA1c (by 1.0%), but
it was not influenced by gender, BMI, diabetes duration,
systolic BP and high GGT level in all subjects (Additional
file 1: Table S2). Among the ALDH2*2 allele carriers,
the duration of diabetes was also added to the risk fac-
tors (HR: 1.11; P = 0.01) and a high GGT level appeared
to be a potential risk factor (HR: 1.91; P = 0.14) for DR
(Additional file 1: Table S2).
No interactive effects between the ALDH2 geno-
types and alcohol intake or the GGT levels were ob-
served (P > 0.05). However, the incidence of DR was
significantly higher in the drinkers with the ALDH2*2
allele than in those with the ALDH2*1/*1 genotype
(HR: 2.61; P = 0.03), while the incidence of DR in the
non-drinkers did not differ significantly between the
ALDH2*2 allele carriers and non-carriers. Moreover,
the incidence of DR in the ALDH2*2 allele carriers
with a high GGT level was significantly higher than
that observed in the non-carriers with a high or lowGGT level (HR: 2.45; P = 0.03; and HR: 2.63; P = 0.03,
respectively) (Table 1, Figure 1b).
The demographic characteristics of the subjects stratified
by the combination of the ALDH2 genotypes and the GGT
level at baseline are shown in Table 2. The mean values of
BMI, BP and the levels of transaminases and the prevalence
of hypertension were significantly higher in the subjects
with a high GGT level than in those with a low GGT
level, irrespective of the ALDH2 genotype. Among the non-
carriers, the frequency of drinkers was significantly higher
in the subjects with a high GGT level than in those with a
low GGT level, and a high GGT level was most significantly
associated with drinking habits (Tables 2 and 3). Among
the ALDH2*2 allele carriers, the frequency of drinkers
was comparable between the subjects with high and
low GGT levels, and a high GGT level was significantly
associated with multiple factors, including an ever-smoking
habit, hypertension, high systolic and diastolic BP and
a high BMI.
The longitudinal changes in the GGT values during
the observation period are shown in Table 4. The GGT
values were significantly higher in the subjects with DR
than in those without, and the difference was significant
in the ALDH2*2 allele carriers (adjusted β: 12.30 IU/L;
P = 0.02), but not in the non-carriers (adjusted β: 5.48 IU/
L; P = 0.65). Only two subjects were newly identified to be
drinkers, while the remaining subjects did not change their
drinking habits during the observation period.
Discussion
To the best of our knowledge, this is the first report of a
significant association between the ALDH2*2 allele and the
incidence of DR. In this retrospective longitudinal study of
Japanese subjects with type 2 DM, an alcohol drinking
habit, especially a high serum GGT level further increased
the risk of DR in the ALDH2*2 allele carriers; however,
these factors did not affect the risk in the non-carriers.
The allelic variant at rs671, ALDH2*2, is common in East
Asians; however, it is very rare in other ethnic groups
[4,6-8,12,13]. This point mutation alters the enzyme activity
in a partially negative dominant fashion, and the variant
homozygotes virtually lack any enzyme activity in vivo
owing to its extremely high Km for coenzyme nicotinamide
adenine dinucleotide (NAD+) and a much lower Vmax
[12]. There is substantial evidence that the overproduction
of reactive aldehydes such as methylglyoxal, glyoxal and
4-HNE results in protein carbonylation and activates mul-
tiple pathogenetically relevant pathways [9]. The structural
and functional changes resulting from the increased for-
mation of AGEs in the early metabolic environment are
implicated in the development and progression of micro-
and macrovascular complications in the long run, and are
referred to as “metabolic memory” [3-5,14]. For instance,
4-HNA forms Michael adducts with dimethylarginine
Table 1 Association between the risk of DR and the combination of the ALDH2 genotypes and the serum GGT levels
GGT levels† ALDH2 genotype n HR‡ (95% CI) P-value HR‡ (95% CI) P-value
Low *1/*1 genotype 58 1 - - -
*2 allele carrier 59 1.60 (0.77 - 4.09) 0.25 - -
High *1/*1 genotype 85 1.15 (0.53 - 2.49) 0.73 1 -
*2 allele carrier 32 2.63 (1.12-6.18) 0.03 2.45 (1.10-5.48) 0.03
†GGT was dichotomized by the near-median 37 IU/L for the males and 26 IU/L for the females.
‡Adjusted by gender, BMI, duration of diabetes, HbA1c and systolic BP.
DR, diabetic retinopathy; ALDH2, aldehyde dehydrogenase 2; GGT, γ-glutamyltransferase; HR, hazard ratio; CI, confidence interval; BMI, body mass index; HbA1c,






*2 allele, low GGT




Figure 1 Kaplan-Meier curves for diabetic retinopathy-free survival during the observation period. The curves are described according to
the ALDH2 genotype (a) and the combination of the ALDH2 genotype and the serum GGT level (b). Adjusted for gender, body mass index,
duration of diabetes, hemoglobin A1c and systolic blood pressure. ALDH2 aldehyde dehydrogenase 2, GGT γ-glutamyltransferase.
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Table 2 Clinical characteristics of the subjects stratified by the combination of the ALDH2 genotype and the serum
GGT level at baseline
GGT levels† Low High P-value
ALDH2 genotype *1/*1 *2 allele *1/*1 *2 allele
(n = 58) (n = 85) (n = 59) (n = 32)
Female (%) 37.9 28.8 31.8 37.5 0.69
Age (years) 57.6 ± 11.0 60.3 ± 9.7 57.5 ± 12.4 56.9 ± 11.0 0.40
Age of diagnosis (years) 47.5 ± 10.9 51.9 ± 11.1 49.4 ± 12.2 51.1 ± 9.2 0.18
Diabetes duration (years) 10.0 ± 8.7 8.3 ± 5.4 7.9 ± 7.0 6.1 ± 5.2 0.07
BMI (kg/m2) 23.2 ± 3.6 23.2 ± 2.9 24.8 ± 4.2 25.8 ± 4.0 < 0.01
Casual plasma glucose (mmol/L) 10.9 ± 4.6 11.4 ± 5.0 11.7 ±5.9 11.6 ± 3.4 0.85
HbA1c (%) 8.4 ± 2.1 8.5 ± 2.2 8.7 ± 2.1 9.2 ± 1.8 0.36
Systolic BP (mmHg) 133.5 ± 19.5 131.5 ± 20.8 141.7 ± 17.5 143.7 ± 20.7 < 0.01
Diastolic BP (mmHg) 80.9 ± 10.9 79.5 ± 12.3 86.2 ± 12.0 87.4 ± 11.8 < 0.01
Triglycerides (mmol/L) 1.3 ± 0.9 1.6 ± 1.5 2.6 ± 2.4 1.9 ± 0.8 < 0.01
HDL cholesterol (mmol/L) 1.6 ± 0.5 1.4 ± 0.4 1.4 ± 0.3 1.4 ± 0.3 0.08
LDL cholesterol (mmol/L) 3.1 ± 0.7 3.2 ± 0.7 3.1 ± 0.8 3.4 ± 0.8 0.21
AST (IU/L) 21.0 ± 5.1 21.6 ± 5.3 39.5 ± 24.4 37.7 ± 20.7 < 0.01
ALT (IU/L) 20.9 ± 9.2 20.7 ± 7.2 49.7 ± 37.8 50.3 ± 36.4 < 0.01
GGT (IU/L) 20.8 ± 7.9 21.4 ± 7.8 77.7 ± 78.7 60.6 ± 37.8 < 0.01
Hypertension (%) 44.8 42.4 64.7 68.8 < 0.01
Dyslipidemia (%) 56.9 64.4 75.3 71.9 0.12
Ever smoker (%) 48.2 43.1 54.2 50.0 0.64
Drinker (%) 56.9 30.5 72.9 28.1 < 0.01
Therapy components
Hypoglycemic agents
Oral hypoglycemic agents (%) 72.4 67.8 64.3 75.0 0.65
Insulin (%) 22.4 10.2 7.1 3.1 0.02
Antihypertensive agents
ACE inhibitors or ARBs (%) 10.3 6.8 13.1 34.4 < 0.01
Others (%) 19.0 11.9 21.4 28.1 0.25
Agents for hyperlipidemia
Fibrates (%) 1.7 1.7 2.4 0.0 1.00
Statins (%) 3.4 11.9 9.5 9.4 0.37
Others (%) 0.0 1.7 0.0 0.0 0.64
Data are percentages or mean ± standard deviation.
†GGT was dichotomized by the near-median 37 IU/L for the males and 26 IU/L for the females.
ALDH2, aldehyde dehydrogenase 2; GGT, γ-glutamyltransferase; BMI, body mass index; HbA1c, hemoglobin A1c; BP, blood pressure; HDL, high-density lipoprotein;
LDL, low-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ACE, angiotensin converting enzyme; ARB, angiotensin II
receptor blocker.
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DDAH1, which is the major enzyme responsible for
eliminating asymmetric dimethylarginine (ADMA) in the
human endothelium [15]. Derangement of the L-arginine-
nitric oxide pathway by ADMA has been implicated as
an important factor contributing to endothelial dys-
function [15,16]. Therefore, elevated plasma levels of
ADMA caused by the genetic or metabolic inactivation
of DDAH1 have been reported to be associated withmicro- and macrovascular diabetic complications [15,16].
ALDH2 detoxifies the reactive aldehydes in the vascula-
tures. Consequently ALDH2 dysfunction can result in the
accelerated accumulation of aldehydes and the develop-
ment of vascular complications, such as DR [4-6,8,9].
ALDH2*2 allele carriers exhibit a marked rise in the
level of acetaldehyde in the blood and develop acute cardio-
vascular reactions, such as facial flushing, tachycardia and
orthostatic hypotension, following alcohol consumption
Table 3 Factors associated with the serum GGT level
stratified by the ALDH2 genotype
ALDH2*1/*1 genotype ALDH2*2 allele carrier
β SE P value β SE P value
Age −0.37 0.48 0.45 −0.70 0.30 0.02
Diabetes duration −0.75 0.72 0.30 −1.38 0.57 0.02
BMI 0.52 1.39 0.71 1.80 0.87 0.04
Systolic BP −0.22 0.30 0.94 0.29 0.14 0.046
Diastolic BP 0.50 0.47 0.30 0.62 0.24 0.01
Triglycerides 0.22 0.03 < 0.01 0.07 0.03 0.02
AST 1.48 0.24 < 0.01 0.97 0.18 < 0.01
ALT 0.85 0.16 < 0.01 0.56 0.10 < 0.01
Hypertension 1.10 11.33 0.92 13.34 6.12 0.03
Ever smokers 13.23 11.46 0.25 16.48 6.09 < 0.01
Drinkers 26.07 11.68 0.03 8.79 6.80 0.20
HbA1c 4.23 2.64 0.11 1.15 1.52 0.45
GGT, γ-glutamyltransferase; ALDH2, aldehyde dehydrogenase 2; SE, standard
error; BMI, body mass index; BP, blood pressure; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; HbA1c, hemoglobin A1c.
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genetic modifier of drinking behavior and reduces the
risk of alcohol-related diseases, such as alcoholism, alcohol-
related liver cirrhosis, chronic pancreatitis, DM and hyper-
tension [5-8,12,17]. Past studies [18,19] and this study have
shown that alcohol intake is not an independent risk factor
for DR. In this study, however, the ALDH2*2 allele was
a significant risk for DR only in drinkers. Light to mod-
erate alcohol intake is known to reduce the incidence
of macrovascular diseases in a U-shaped fashion [20].
Ethanol at low concentrations is metabolized by low
Km alcohol dehydrogenase and ALDH2, thus resulting
in the production of reduced NAD+ [21]. These reactions
create a reductive environment, decrease oxidative stress
and prevent the secondary production of aldehydes via
lipid peroxidation. Therefore, chronic low ethanol intake
confers a beneficial effect on the vasculature primarily
through its ability to increase the antioxidant capacity and
lower the amount of AGEs [20,21]. Conversely, the lack ofTable 4 The change in the average GGT value stratified by th
ALDH2*1/*1 genotype
With the DR Without the DR
Observation period n GGT (IU/L) n GGT (IU/L)
0 26 66.1 ± 96.5 117 55.4 ± 76.2
2 22 63.6 ± 72.6 104 47.7 ± 62.7
4 20 47.3 ± 57.2 77 41.2 ± 44.6
6 16 61.4 ± 56.9 60 40.9 ± 45.5
8 10 59.4 ± 46.4 27 34.0 ± 19.5
Data are mean ± standard deviation.
GGT, γ-glutamyltransferase; ALDH2, aldehyde dehydrogenase 2; DR, diabetic retinopALDH2 activity increases the levels of acetaldehydes and
other reactive aldehydes, and thus induces oxidative stress
even after light alcohol intake [21]. Previously, we reported
that alcohol intake increases the risk of hypertension and
elevates systolic and diastolic BP much more significantly
in ALDH2*2 allele carriers than in non-carriers in a dose-
dependent manner [8]. Taken together, the ALDH2*2 allele
is thus considered to be an independent genetic risk factor
for alcohol-related microvascular and macrovascular
diseases [4,6,8]. One study showed that alcohol intake
was associated with a lower risk of all microvascular
complications in a U-shaped fashion among Type 1 dia-
betes patients in Europe, where the ALDH2*2 allele is very
rare [22]. The present study also showed drinkers with the
ALDH2*1/*1 genotype tended to be at a lower risk for the
incidence of DR than non-drinkers (data not shown). These
facts suggest that ALDH2 protects the vasculature from
reactive aldehydes in relation to the beneficial effects of
mild to moderate alcohol intake [6,8,20-22].
We further investigated the data after taking into ac-
count the GGT level, a valid marker of excessive alcohol
consumption [10,23] The occurrence of DR was signifi-
cantly higher in the ALDH2*2 allele carriers with a high
GGT level at baseline than in the non-carriers with a high
or low GGT level (Table 1, Figure 1b). The GGT levels in
non-carriers should be dependent on alcohol intake, be-
cause the frequency of drinkers was significantly higher
among the non-carriers with a high GGT level (Table 2),
and a high GGT level was most significantly associated
with drinking habits (Table 3). Among the ALDH2*2
allele carriers, the frequency of drinkers was comparable
between the subjects with high and low GGT levels
(Table 2), and a high GGT level was significantly asso-
ciated with multiple cardiovascular risk factors, such
as an ever-smoking habit, hypertension, high systolic and
diastolic BP and a high BMI (Table 3). GGT metabolizes
extracellular glutathione (GSH), allowing precursor amino
acids to be reused for intracellular GSH synthesis; hence,
a modest increase within the normal range may be an
early marker of oxidative stress [10]. Positive associations
have been reported between the serum GGT level and thee ALDH2 genotype
ALDH2*2 allele carrier
With the DR Without the DR
P value n GGT (IU/L) n GGT (IU/L) P value
0.54 26 42.7 ± 40.3 65 31.5 ± 24.2 0.11
0.30 23 37.7 ± 24.9 56 28.6 ± 18.3 0.08
0.61 20 38.2 ± 25.2 39 27.3 ± 16.9 0.05
0.20 16 31.6 ± 14.9 28 20.3 ± 7.7 < 0.01
0.12 14 36.4 ± 24.0 16 20.9 ± 8.4 0.02
athy.
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disease death in DM patients, diabetic nephropathy
and DR [11,23-26]. In this study, the GGT values dur-
ing the observation period were significantly higher in
the subjects with DR than in those without among the
ALDH2*2 allele carriers (Table 4). The pathophysio-
logical mechanisms underlying these associations have
not been elucidated; however, insulin resistance, oxidative
stress and chronic low-grade systemic inflammation may
be involved [10,11], and these pathological conditions were
also reported in the ALDH2*2 carriers at an early stage
of glucose intolerance [27]. When our present findings
and these previous findings are combined, it appears that
a high GGT level in ALDH2*2 carriers may have some
predictive value for DR.
The crucial limitations of the present study include
the retrospective study design and small sample size.
In addition, the details of the subjects’ drinking habits,
the influence of drug therapy were uncertain.
In conclusion, we herein demonstrated that the ALDH2*2
allele is an independent risk factor for the incidence of DR.
The association between the ALDH2 genotype and the
incidence of DR was significant among drinkers and
subjects with a high GGT level. These findings provide
additional evidence that ALDH2 protects both the mi-
crovasculature and macrovasculature against the reactive
aldehydes generated under conditions of sustained oxi-
dative stress, although further investigations in larger
cohorts are needed to verify the results.
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